The global immunohistochemistry market size was valued at USD 2.92 billion in 2025 and is projected to grow from USD 3.13 billion in 2026 to USD 5.39 billion by 2034, registering a CAGR of 7.05% during the forecast period from 2026 to 2034. North America dominated the immunohistochemistry market with a market share of 38.5% in 2025.
Immunohistochemistry (IHC) is a laboratory technique used to detect specific proteins or antigens in tissue samples by using antibodies that bind to target molecules. The bound antibodies are visualized with colored dyes or markers, allowing researchers and healthcare professionals to examine the location and distribution of proteins under a microscope. Immunohistochemistry is widely used in pathology, cancer diagnosis, biomedical research, and disease investigation to identify abnormal cells, classify tumors, study tissue characteristics, and support accurate clinical decision-making.
Download a Free Sample To learn more about this report,
AI-Powered Digital Pathology Expands IHC Interpretation
The immunohistochemistry market is increasingly integrating artificial intelligence and digital pathology into tissue-analysis workflows. AI-assisted image analysis can quantify biomarker expression and support more consistent interpretation than manual scoring alone. The combination of IHC staining with computational pathology is particularly relevant in oncology, where biomarker results can influence treatment selection. These developments are supporting immunohistochemistry market growth as laboratories adopt technologies that improve the efficiency and consistency of tissue-based diagnosis.
In April 2025, Roche received FDA Breakthrough Device Designation for its VENTANA TROP2 (EPR20043) RxDx Device, an IHC assay combined with a digital pathology algorithm for evaluating TROP2 expression in non-small cell lung cancer tissue.
Companion Diagnostics Strengthen Biomarker-Based Oncology
IHC is increasingly being incorporated into companion diagnostics that identify patients who may benefit from specific targeted therapies. These assays connect tissue biomarker assessment with therapeutic decision-making and are expanding the clinical role of IHC beyond conventional tumor classification. The continued authorization of biomarker-specific IHC tests is contributing to changes in immunohistochemistry market trends and strengthening the connection between pathology laboratories and precision oncology.
In June 2026, the FDA approved the VENTANA PTEN (SP218) RxDx Assay as a companion diagnostic for identifying prostate cancer patients who may be eligible for TRUQAP in combination with abiraterone. The qualitative IHC assay assesses PTEN protein in prostate tumor tissue.
Growing Use of Biomarker Testing for Treatment Selection
The increasing use of biomarker-guided cancer therapies is strengthening demand for IHC assays that identify clinically relevant protein expression in tumor tissue. Companion diagnostics can help determine whether a patient is likely to benefit from a particular treatment, making reliable biomarker testing increasingly important in oncology workflows. As targeted therapies expand, pathology laboratories require validated assays that can provide treatment-relevant information, supporting immunohistochemistry market demand.
In May 2025, the FDA approved Roche's VENTANA MET (SP44) RxDx Assay for assessing MET protein expression in non-squamous non-small cell lung cancer tissue. The IHC assay was authorized as a companion diagnostic to help identify patients eligible for treatment with EMRELIS.
Standardization Requirements Increase Testing Complexity
IHC testing requires controlled tissue preparation, staining procedures, antibody selection, quality control, and interpretation to achieve reliable results. Differences in laboratory procedures and scoring approaches can affect reproducibility, while validation and quality-assurance requirements add operational work. These factors can increase the resources required to introduce new IHC assays and maintain consistent testing performance across laboratories.
In January 2026, the FDA approved manufacturing-process changes for the VENTANA anti-MSH6 (SP93) Antibody, illustrating the ongoing need for controlled manufacturing and quality processes for clinically used IHC reagents.
Expansion of IHC Into New Biomarker and Companion-Diagnostic Applications
The growing number of therapies linked to tissue biomarkers is creating opportunities for IHC manufacturers to develop assays for additional cancer types and molecular targets. New companion diagnostics can extend established staining platforms into treatment-selection pathways while creating demand for validated antibodies, detection systems, and laboratory workflows. This expansion is creating new immunohistochemistry market opportunities as precision oncology increases the number of clinically actionable tissue biomarkers.
In June 2026, the FDA added the VENTANA PTEN (SP218) RxDx Assay to its list of authorized companion diagnostic devices. The assay identifies PTEN protein loss in prostate cancer tissue and is linked to treatment eligibility for TRUQAP in combination with abiraterone.
Maintaining Reproducibility Across IHC Testing and Interpretation
IHC results can be affected by pre-analytical conditions, staining procedures, antibody performance, instrument settings, and interpretation methods. Maintaining reproducibility becomes particularly important when biomarker results determine eligibility for targeted treatment. Laboratories therefore need appropriate validation, controls, standardized procedures, and qualified interpretation to ensure that results remain clinically reliable.
In February 2024, the College of American Pathologists published an updated evidence-based guideline for analytical validation of IHC assays. The recommendations addressed predictive and nonpredictive IHC assays and included considerations for verification and revalidation, highlighting the continuing importance of analytical consistency in clinical IHC testing.
Antibodies Segment Dominated the Immunohistochemistry Market with 41.2% Share in 2025
The antibodies segment dominated the global immunohistochemistry market with a 41.2% share in 2025, driven by their essential role in detecting and identifying specific proteins within tissue samples. Antibodies are widely used in disease diagnosis, cancer biomarker identification, pathology research, and precision medicine due to their high specificity and accuracy. The increasing prevalence of cancer and other chronic diseases, coupled with growing adoption of personalized medicine and biomarker-based diagnostics, continues to strengthen demand for antibodies in immunohistochemistry applications.
The equipment segment continues to account for a significant share of the market as laboratories and hospitals increasingly invest in automated staining systems, slide scanners, and imaging platforms to improve diagnostic efficiency and accuracy. The reagents segment remains an important contributor due to the recurring need for buffers, chromogens, and detection systems in routine laboratory testing. Meanwhile, the kits segment is witnessing steady growth as healthcare providers increasingly adopt ready-to-use immunohistochemistry kits that simplify workflows, reduce testing time, and ensure standardized diagnostic results.
Request Customizationto receive a tailored report.
Drug Testing Segment is Projected to Register the Fastest Growth in the Immunohistochemistry Market at a CAGR of 8.23%
The drug testing segment is projected to register the fastest growth in the immunohistochemistry market at a CAGR of 8.23% during 2026–2034, driven by increasing pharmaceutical research, expanding clinical trials, and growing demand for biomarker-based drug development. Immunohistochemistry plays a critical role in evaluating drug efficacy, identifying therapeutic targets, assessing tissue responses, and supporting precision medicine initiatives. Rising investments in oncology research and biologics development continue to accelerate the adoption of immunohistochemistry in pharmaceutical and biotechnology applications.
The diagnostics segment continues to dominate the market due to the widespread use of immunohistochemistry in identifying cancers, infectious diseases, and other pathological conditions. Hospitals and diagnostic laboratories rely heavily on immunohistochemical staining to support accurate disease diagnosis, classify tumor types, and guide treatment decisions, making diagnostics the primary application area for immunohistochemistry technologies.
Hospitals Segment Dominated the Immunohistochemistry Market with 43.8% Share in 2025
The hospitals segment dominated the global immunohistochemistry market with a 43.8% share in 2025, driven by the growing number of cancer diagnoses, increasing surgical biopsy procedures, and rising adoption of advanced pathology testing. Hospitals are equipped with specialized pathology laboratories and skilled healthcare professionals, enabling them to perform a high volume of immunohistochemistry tests for disease diagnosis, prognosis, and treatment planning. Continuous investments in healthcare infrastructure and precision diagnostics continue to support the leadership of this segment.
The diagnostic laboratories segment continues to witness strong growth as demand for specialized pathology services and high-throughput diagnostic testing increases. These laboratories are expanding their use of automated immunohistochemistry platforms to improve testing efficiency and diagnostic accuracy. The research institutes segment also remains an important contributor, with academic organizations and biomedical research centers utilizing immunohistochemistry extensively for disease mechanism studies, biomarker discovery, and the development of innovative therapeutic approaches.
Speak to an Analystto discuss market opportunities.
North America accounted for the largest share of the global immunohistochemistry market, representing 38.5% of total revenue and reaching USD 1.12 billion in 2025. The region continues to lead due to the high prevalence of cancer, advanced healthcare infrastructure, and increasing adoption of precision medicine. Growing investments in pathology laboratories, rising demand for biomarker-based diagnostics, and continuous advancements in diagnostic technologies continue to drive market growth across the region.
The US market was valued at approximately USD 0.97 billion in 2025, making it the largest contributor in North America. Increasing cancer screening programs, growing adoption of personalized medicine, expanding investments in clinical diagnostics, and rising demand for advanced pathology testing continue to strengthen market growth.
Canada's market reached approximately USD 0.15 billion in 2025. Growing healthcare expenditure, increasing research in oncology diagnostics, and expanding use of immunohistochemistry in disease diagnosis are contributing to steady market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific accounted for 22.6% of the global immunohistochemistry market, valued at USD 0.66 billion in 2025, and is projected to register the fastest CAGR of 9.18% during the forecast period. Rising cancer incidence, expanding healthcare infrastructure, increasing investments in diagnostic laboratories, and growing awareness of early disease detection continue to drive regional market growth. Government support for healthcare modernization and biotechnology research is further accelerating market expansion.
Japan's market generated approximately USD 0.12 billion in 2025. Strong adoption of advanced diagnostic technologies, increasing cancer research activities, and continued investment in precision medicine continue to support market growth.
China accounted for the largest share of the Asia Pacific market, reaching approximately USD 0.40 billion in 2025. Expanding healthcare infrastructure, increasing demand for cancer diagnostics, growing investments in biotechnology, and rising adoption of automated pathology systems continue to drive market expansion.
Europe accounted for 28.4% of the global immunohistochemistry market, reaching USD 0.83 billion in 2025, and is projected to grow at a CAGR of 7.16% during the forecast period. The regional market is supported by well-established healthcare systems, increasing demand for accurate diagnostic testing, and growing adoption of personalized medicine. Continuous investments in life sciences research and pathology services are further strengthening market growth.
The UK market was valued at approximately USD 0.18 billion in 2025. Rising investments in cancer diagnostics, increasing use of biomarker testing, and expanding pathology laboratory capabilities continue to support market growth.
Germany's market accounted for approximately USD 0.22 billion in 2025. The country's strong healthcare infrastructure, growing demand for advanced diagnostic technologies, and continued investment in biomedical research continue to accelerate market expansion.
Middle East & Africa accounted for 4.4% of the global immunohistochemistry market, totaling USD 0.13 billion in 2025. Increasing healthcare investments, expanding diagnostic laboratory networks, and growing awareness of early cancer detection are supporting market growth across the region. Government initiatives to improve healthcare access and strengthen pathology services are expected to create additional opportunities during the forecast period.
The UAE market was valued at approximately USD 0.03 billion in 2025. Growing investments in healthcare infrastructure, increasing adoption of advanced diagnostic technologies, and expanding oncology care services continue to support market development.
Africa's market reached approximately USD 0.10 billion in 2025. Improving access to diagnostic healthcare services, increasing cancer awareness, expanding pathology laboratory capacity, and rising investments in healthcare infrastructure are creating long-term growth opportunities across the region.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Europe Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2034
Asia Pacific Genetic Testing Market Size, 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
U.S Direct to Consumer Laboratory Testing Market Size, Share and Forecast to 2034
Non-invasive Prenatal Testing Market Size, Share, Growth, 2034
Vaccines Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com